What question did this study set out to answer?

To evaluate the impact of BTK inhibition on the efficacy of CD19-CAR T-cell therapy in Mantle Cell Lymphoma.

December 8, 2025Blood

Enhancing the expansion of Naïve, potent T-cells via BTK inhibition reinvigorates CD19-CAR T-cell immunity and boosts antitumor efficacy in relapsed Mantle Cell Lymphoma

View Full Paper

Ask AI

Bookmark

To evaluate the impact of BTK inhibition on the efficacy of CD19-CAR T-cell therapy in Mantle Cell Lymphoma.
Generated CD19-CAR T cells from healthy donor T cells using lentiviral transduction with BTK inhibitors.
Assessed T-cell activation, proliferation, and metabolic activity.
Evaluated CAR T-cell effector functions through cytokine secretion and cytotoxicity assays.
Used in vivo models, including patient-derived xenografts, to assess antitumor efficacy.
BTK inhibition preserved naïve-like features and enhanced metabolic fitness in CAR T cells.
CAR T cells showed robust secretion of type I cytokines and significant cytotoxic responses.
Treatment with ibrutinib significantly enhanced tumor clearance and survival in xenograft models.
Both ibrutinib and pirtobrutinib demonstrated comparable antitumor efficacy in preclinical models.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical findings reveal BTK inhibition improves antitumor efficacy and T-cell function in relapsed mantle cell lymphoma patients' CAR T-cell therapy.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d777 https://doi.org/10.1182/blood-2025-1785

View Full Paper

Ask AI

Bookmark

Implication

Preclinical findings reveal BTK inhibition improves antitumor efficacy and T-cell function in relapsed mantle cell lymphoma patients' CAR T-cell therapy.

Enhancing the expansion of Naïve, potent T-cells via BTK inhibition reinvigorates CD19-CAR T-cell immunity and boosts antitumor efficacy in relapsed Mantle Cell Lymphoma

Key Points

Discussion

Implication

Cite This Study

Enhancing the expansion of Naïve, potent T-cells via BTK inhibition reinvigorates CD19-CAR T-cell immunity and boosts antitumor efficacy in relapsed Mantle Cell Lymphoma

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider